SUMMIT, N.J., September 18, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today unveiled new analyses that underscore the potential of influenza vaccines in alleviating the burden of seasonal ...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG, ...

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.

CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’. The world-class facility will ...

Are you interested in receiving our latest news? Simply fill out the form below to receive news alerts directly to your inbox. To receive releases from a specific CSL business unit, select customize ...

Thank you for your interest in CSL. We care about your questions and concerns. You can find the best way to contact us from the list below.